Duke Law & Technology Review

eCommerce

CyberCrime

International

SUBSCRIBE TO MAILING LIST

Health & Biotechnology:

RECENT ARTICLES:
REGULATING NANOTECHNOLOGY: A PRIVATE-PUBLIC INSURANCE SOLUTION
	2008 Duke L. & Tech. Rev. 002 Health & Biotechnology 2/13/2008 Nanotechnology promises to revolutionize innovation in nearly every industry. However, nanomaterials’ novel properties pose potentially significant health and environmental risks. Views in the current debate over nanotechnology regulation range from halting all research and development to allowing virtually unregulated innovation. One viable regulatory solution balancing commercialization and risk is the adoption of a mandatory private-public insurance program.

Archived Articles >>>

Title:	Date Posted
ENCOURAGING CORPORATE INNOVATION FOR OUR HOMELAND DURING THE BEST OF TIMES FOR THE WORST OF TIMES: EXTENDING SAFETY ACT PROTECTIONS TO NATURAL DISASTERS	11/2/2006
WHY TECHNOLOGY PROVIDES COMPELLING REASONS TO APPLY A DAUBERT ANALYSIS TO THE LEGAL STANDARD OF CARE IN MEDICAL MALPRACTICE CASES	11/2/2006
WHAT, IF ANY, ARE THE ETHICAL OBLIGATIONS OF THE U.S. PATENT OFFICE?: A CLOSER LOOK AT THE BIOLOGICAL SAMPLING OFINDIGENOUS GROUPS	5/17/2006
ATTACK OF THE CLONES: LEGISLATIVE APPROACHES TO HUMAN CLONING IN THE UNITED STATES	12/7/2005
WHEN THE PUBLIC DOES NOT HAVE A RIGHT TO KNOW: HOW THE CALIFORNIA PUBLIC RECORDS ACT IS DETERRING BIOSCIENCE RESEARCH AND DEVELOPMENT	10/18/2005
TAKING BIOLOGICS FOR GRANTED? TAKINGS, TRADE SECRETS, AND OFF-PATENT BIOLOGICAL PRODUCTS	3/1/2005
DISCLOSURE OF CLINICAL TRIAL DATA: WHY EXEMPTION 4 OF THE FREEDOM OF INFORMATION ACT SHOULD BE RESTORED	2/17/2005
REGULATING INNOVATIVE MEDICINE: FITTING SQUARE PEGS IN ROUND HOLES	1/13/2005
THE MEDICARE PRESCRIPTION DRUG, IMPROVEMENT, & MODERNIZATION ACT OF 2003: ARE WE PLAYING THE LOTTERY WITH HEALTHCARE REFORM?	10/1/2004
ARE BIOTECH CROPS AND CONVENTIONAL CROPS LIKE PRODUCTS? AN ANALYSIS UNDER GATT	10/29/2003
HATCH-WAXMAN REFORM AND ACCELERATED MARKET ENTRY OF GENERIC DRUGS: IS FASTER NECESSARILY BETTER?	8/13/2003
REVIVING INFORMED CONSENT: USING RISK PERCEPTION IN CLINICAL TRIALS	6/9/2003
THE CASE FOR NATIONAL DNA IDENTIFICATION CARDS	1/31/2003
DEFINING A NEW ETHICAL STANDARD FOR HUMAN IN VITRO EMBRYOS IN THE CONTEXT OF STEM CELL RESEARCH	12/10/2002
REGULATING FUNCTIONAL FOODS: PRE- AND POST-MARKET STRATEGY	11/25/2002
GENETIC TESTING IN THE WORKPLACE: THE EMPLOYER'S COIN TOSS	9/5/2002
CUSTOMIZING CONCEPTION: A SURVEY OF PREIMPLANTATION GENETIC DIAGNOSIS AND THE RESULTING SOCIAL, ETHICAL, AND LEGAL DILEMMAS	7/23/2002
APPROPRIATE AIMS: SETTING BOUNDARIES FOR REPROGENETIC TECHNOLOGY	7/17/2002
EGREGIOUS ERROR OR ADMIRABLE ADVANCE: THE MEMORANDUM OF UNDERSTANDING THAT ENABLES FED ERALLY FUNDED BASIC HUMAN EMBRYONIC STEM CELL RESEARCH	10/16/2001
A RECONSIDERATION OF THE PHYSICIANS' IMMUNITY STATUTE	8/6/2001
THE CLONE WARS: THE GROWING DEBATE OVER FEDERAL CLONING LEGISLATION	6/20/2001
WHERE THE WILD WIND BLOWS: GENETICALLY ALTERED SEED AND NEIGHBORING FARMERS	5/3/2001
THE FATE OF GENE PATENTS UNDER THE NEW UTILITY GUIDELINES	2/28/2001

Related Sites: